



# AGENDA

**\*\* Mountain Standard Time \*\***

## THURSDAY, January 6, 2022

18:00 – 20:00 **Welcome Reception**

## FRIDAY, January 7, 2022

6:45 – 7:30

**Breakfast**

7:30 – 8:00

**The Year 2021 in Review**

8:00 – 9:30

**SESSION 1: ONE-STOP SHOP**

8:00 – 8:20

**FXR: Clinical Trial Summary of FXR Agonists**

8:20 – 8:30

Open Mic Discussion

8:30 – 8:50

**FGF-19: Aldafermin Trial Results and Tribulations**

8:50 – 9:00

Open Mic Discussion

9:00 – 9:20

**FGF-21: Cover to Cover FGF-21 Trials**

9:20 – 9:30

Open Mic Discussion

9:30 – 9:50

**Break – Exhibit Hall/Poster Viewing**

9:50 – 10:40

**SESSION 2: LATEST CLINICAL TRIAL RESULTS**

9:50 – 10:25

**Key Congress Presentations**

10:25 – 10:40

**Q&A**

10:40 – 12:00

**SESSION 3: BACK TO BIOLOGIC BASIS OF NASH PROGRESSION**

10:40 – 10:55

**Role of Phage Therapies in Liver Disease**

10:55 – 11:10

**Emerging Data on Lipotoxicity in NASH**

11:10 – 11:25

**Why Is NASH related HCC Resistant to Treatment?**

11:25 – 11:40

**Organoids in NASH therapeutics**

11:40 – 12:00

**Panel Discussion**

12:00 – 16:00

**Interactive Dialogue on NASH Topics**

12:30 – 14:00

**INDUSTRY-SPONSORED EVENT/CME SATELLITE SYMPOSIUM**



# AGENDA

16:00 – 17:40

**SESSION 4: WHAT'S HAPPENING IN MAJOR CONSORTIA ACROSS THE FIELD?**

16:00 – 16:20

**NIMBLE Update**

16:20 – 16:40

**LITMUS Update**

16:40 – 17:00

**Two Oral Presentations**

17:00 – 17:20

**Cirrhosis Network Update**

17:20 – 17:40

**Panel Discussion**

17:40 – 18:00

**Break – Exhibit Hall/Poster Viewing**

18:00 – 19:00

**SESSION 5: ARTIFICIAL INTELLIGENCE PLATFORMS IN NASH TRIALS**

18:00 – 18:15

**New Data on Path AI**

18:15 – 18:30

**New Data on Histoindex**

18:30 – 18:45

**What's Next in AI Platforms in NASH Trials and Future**

18:45 – 19:00

**Panel Discussion**

**\*\* Mountain Standard Time \*\***

## SATURDAY, January 8, 2022

6:45 – 7:30

**Breakfast**

7:30 – 9:40

**SESSION 6: WHAT'S NEW OUT THERE AND HOW TO INTERPRET WHAT IT ALL MEANS**

7:30 – 7:50

**Update from the AASLD NASH Task Force**

7:50 – 8:10

**New Data on Wet Biomarkers**

8:10 – 8:30

**Lessons Learned from Early Pioneers in NASH Drug Development**

8:30 – 8:50

**Combination Therapy Data in 2022: Current Status**

8:50 – 9:10

**New Data on Predicting Treatment Response**

9:10 – 9:40

**Panel Discussion**

9:40 – 10:00

**Break – Exhibit Hall/Poster Viewing**



# AGENDA

10:00 – 12:00

## SESSION 7: NEW TARGETS

10:00 – 10:15

**PNPLA3 Knockdown as Treatment of NASH**

10:15 – 10:30

**HSD17B13 Knockdown and Inhibition as Treatment of NASH**

10:30 – 10:45

**MOTc in the Treatment of NASH**

10:45 – 11:00

**Uncouplers in the Treatment of NASH**

11:00 – 11:15

**TLR-based Therapies in NASH**

11:15 – 11:30

**Mechanisms of VLDL Turnover: Implications in Nash Therapeutics**

11:30 – 12:00

**Panel Discussion**

12:00 – 16:00

**À la Carte Roundtable Discussion Related to Drug Development**

12:30 – 16:00

**INDUSTRY-SPONSORED EVENT/CME SATELLITE SYMPOSIUM**

16:00 – 17:40

## SESSION 8: BASIC SCIENCE

16:00 – 16:20

**Two Oral Presentations**

16:20 – 16:40

**Single Cell Transcriptomics and NASH**

16:40 – 17:00

**Inflammation and Gut Dysbiosis**

17:00 – 17:20

**Integrins and Fibrosis**

17:20 – 17:40

**Overview of Dual/Triple Agonists**

17:40 – 18:00

**Break – Exhibit Hall/Poster Viewing**

18:00 – 19:40

## SESSION 9: NASH ENDPOINTS AND REGULATORY LANDSCAPE

18:00 – 18:20

**Non-cirrhotic Trial Endpoints- Is It Time to Pivot?**

18:20 – 19:00

**Fireside Chat**

19:00 – 19:15

**Cirrhotic Trial Endpoints- Are we Ready for NITs?**

19:15 – 19:40

**Fireside Chat**

19:40 – 19:45

**NASH-TAG 2021 Recap and Future**

19:45 – 21:00

**Farewell Reception**

21:00

**Meeting Adjourn**